📈 Top 5 “Buy / Strong Buy” Stocks for Short-Term Upside (India — November 2025)
- Get link
- X
- Other Apps
📈 Top 5 “Buy / Strong Buy” Stocks for Short-Term Upside (India — November 2025)
The Indian market continues to see strong momentum across select mid and large caps.
Based on TradingView’s Top Gainers list and current Buy / Strong Buy ratings from analysts, here are five stocks that look technically and sentimentally well-placed for near-term upside.
(This post is for information only, not investment advice.)
🔹 1. Navin Fluorine International Ltd (NAVINFLUOR)
Rating: Buy
Sector: Specialty Chemicals
Ideal Entry: ₹4,850 – ₹4,950
Target Zone: ₹5,250 – ₹5,400
Stop-Loss: ₹4,720
Why it matters:
Navin Fluorine has strong visibility in high-margin specialty-chemical and CDMO segments.
Jefferies and ICICI Securities maintain Buy ratings citing robust order flow and earnings CAGR.
Watch for delivery volumes above 45 % to confirm follow-through.
🔹 2. TD Power Systems Ltd (TDPOWERSYS)
Rating: Buy
Sector: Engineering / Power Equipment
Ideal Entry: ₹330 – ₹345
Target Zone: ₹375 – ₹390
Stop-Loss: ₹320
Why it matters:
A recent Goldman Sachs block deal boosted sentiment.
Exports and order inflow remain healthy.
Momentum remains positive as long as price stays above ₹320.
🔹 3. TARC Ltd (TARC)
Rating: Strong Buy
Sector: Real Estate (NCR)
Ideal Entry: ₹215 – ₹225
Target Zone: ₹245 – ₹260
Stop-Loss: ₹208
Why it matters:
TARC owns premium land banks in Delhi NCR and benefits from strong residential demand.
The chart shows a breakout continuation; volatility is high, so partial profit booking near 10 % gain is prudent.
🔹 4. Chennai Petroleum Corporation (CHENNPETRO)
Rating: Strong Buy
Sector: Energy / Refining
Ideal Entry: ₹530 – ₹545
Target Zone: ₹585 – ₹600
Stop-Loss: ₹518
Why it matters:
Refining-margin uptick and PSU energy momentum support near-term gains.
Volumes remain strong — ideal for short-term swing traders targeting 1–2 weeks.
🔹 5. Jenburkt Pharma Ltd (JENBURPH)
Rating: Strong Buy
Sector: Pharmaceuticals
Ideal Entry: ₹600 – ₹620
Target Zone: ₹670 – ₹690
Stop-Loss: ₹585
Why it matters:
Small-cap pharma with improving margins and low debt.
Stock has broken above ₹580 resistance with steady RSI strength.
Use limit orders due to low liquidity.
⚠️ Disclaimer
This article is for educational and informational purposes only.
It is not financial advice. Stock markets are volatile; always do your own due diligence or consult a SEBI-registered advisor before investing.
Would you like me to make this SEO-optimized with meta-description, image placeholders, and internal links (for Blogger’s search ranking)? I can generate that version next.
- Get link
- X
- Other Apps
Comments
Post a Comment